Chronic Postsurgical Pain: The Complication With a Diagnosis Code and No Line on the Consent Form

Every cosmetic surgery consent form mentions pain. It appears in the same sentence as swelling and bruising, framed as a temporary cost that resolves on a schedule, and in the overwhelming majority of cases that framing is correct. Discomfort peaks in the first days, fades over weeks, and is gone.

There is a second thing that also gets called pain, and it is not the same condition. It is pain that is still present three months, six months, or two years after the operation, often burning or electrical rather than sore, often triggered by a bra strap or a waistband rather than by activity, and frequently sitting in an area that is simultaneously numb. It has a name, a definition, and a diagnostic code. It is called chronic postsurgical pain, and it is one of the most studied complications in general surgery and one of the least discussed in aesthetic surgery.

The asymmetry is odd, because the operations where it is reported most often are precisely the operations this industry performs most. Breast surgery sits near the top of every published risk table. Abdominal wall surgery is not far behind. And yet a patient can read a stack of cosmetic consent forms and never encounter the concept as a distinct outcome, only as an intensified version of ordinary soreness that will presumably go away.

What chronic postsurgical pain actually is, and why three months is the line

The short answer: it is pain that develops or worsens after an operation and persists beyond the expected healing period, conventionally set at three months, localized to the surgical field or to the territory of a nerve in that field, with other explanations excluded.

That definition is not editorial. The eleventh revision of the International Classification of Diseases, which took effect in 2022, created chronic postsurgical and posttraumatic pain as a formal diagnostic category, following work by an International Association for the Study of Pain task force published in the journal Pain in 2019. Before that, chronic pain after surgery had no code of its own. It was recorded, when it was recorded at all, as a symptom attached to something else. That is a large part of why the condition has been invisible in outcome reporting.

The three month threshold is a convention rather than a biological boundary, chosen because it reliably sits past the point where tissue healing explains the symptom. Two other elements of the definition do more work than the clock:

• Other causes must be excluded. Pain from an untreated infection, an unrecognized hernia, a hematoma, a malpositioned implant, or a capsule under tension is not this diagnosis. It is the other diagnosis, and it has its own treatment.
• The pain is often neuropathic in character. Patients describe burning, shooting, electric, or crawling sensations, hypersensitivity to light touch, and pain triggered by clothing. This is nerve-generated pain, and it behaves differently from tissue pain, including in what medications work on it.

Clinicians separate the two with structured screening questionnaires. The DN4, the LANSS, and painDETECT are short instruments that score descriptors and simple bedside tests to estimate how likely a given pain is neuropathic. None of them is diagnostic on its own. All of them are more rigorous than the question most patients actually get asked, which is whether the pain is better than last month.

The distinction matters because the two categories respond to different things. Tissue pain answers to anti-inflammatories and time. Neuropathic pain frequently does not, which is why a patient six months out can be taking ibuprofen around the clock with no effect and conclude, reasonably but wrongly, that nothing can be done.

"

Numbness and pain in the same patch of skin sounds like a contradiction. It is actually the most characteristic finding in the condition, and it is the clearest sign that a nerve, not a wound, is generating the symptom.

"

That combination deserves its own note, because patients report it constantly and it gets dismissed. A region that is partly numb and simultaneously painful is not a confused description. It is the expected consequence of a nerve that has been injured and is signaling abnormally: the ordinary touch fibers are impaired, and the pain fibers are firing without provocation. The normal sensory recovery pattern, and the timeline it follows when things go right, is covered in what nerve recovery after surgery actually looks like. This article is about what happens in the fraction of cases where it does not.

The numbers are highest exactly where aesthetic surgery does the most work

The short answer: across all surgery types, persistent pain is commonly reported in something like ten to fifty percent of patients depending on the operation and the definition, with severe and disabling pain in a much smaller subset, and breast and abdominal wall procedures sit at the higher end of that range.

The most cited framing comes from a 2006 review in The Lancet by Kehlet, Jensen, and Woolf, which pulled the surgical literature together and concluded that persistent postsurgical pain affects a substantial minority of patients across common operations, with a smaller group, often quoted at roughly two to ten percent, reporting pain severe enough to interfere with daily life. Those figures come overwhelmingly from reconstructive, oncologic, orthopedic, and general surgery. Cosmetic surgery contributes a thin slice of the evidence, which is the first honest caveat in this article.

What does exist for breast surgery is consistent in direction and inconsistent in magnitude. Survey studies of women after breast operations, including cosmetic augmentation and reduction, have reported persistent pain at long-term follow-up in figures ranging from the low teens to well over a third, and the variation is not noise. It is definitional. A study that asks "do you have any pain in the breast area" will produce a number several times larger than one that asks about pain of at least moderate intensity present on most days and interfering with function. Both get published. Both get quoted. Neither is wrong. They are measuring different things.

That is the single most important thing to understand about these percentages: there is no agreed measurement standard, so any specific number quoted at you, high or low, is a choice of definition as much as a finding. The same problem distorts the satisfaction figures examined in where plastic surgery satisfaction numbers come from, and for the same reason.

A few procedure-specific observations survive the noise:

• Breast augmentation and reduction both appear repeatedly in the persistent pain literature. Reduction and lift involve more extensive tissue rearrangement, while augmentation adds a device and a pocket, and both routes reach the same intercostal nerves.
• Abdominoplasty and panniculectomy involve wide undermining of the abdominal wall and, in a full repair, plication of the fascia. Persistent abdominal wall pain is well described after hernia repair, an operation with meaningful mechanical overlap, and the tummy tuck versus panniculectomy distinction matters here because the muscle repair is the part that alters wall mechanics.
• Operations involving the ribs or the chest wall carry the strongest signal of all, which is one of the reasons the case against rib removal for waist narrowing is as severe as it is. The thoracic surgery literature on chronic pain after rib and intercostal nerve manipulation is not encouraging.
• Chest masculinization and large-volume reduction share the nerve anatomy of the breast operations above, discussed further in what top surgery actually is as a contouring operation.

None of this makes these operations unwise. It makes the risk a real number rather than an absent one, and a real number belongs in a consultation.

Why it happens: the nerves in the field, and the neuroma at the end of one

The short answer: an operation cuts, stretches, or entraps small sensory nerves, most of them heal, and in a minority the injured nerve either forms a disorganized bundle of regenerating fibers called a neuroma or drives the spinal cord into a persistently amplified state.

Take the breast as the worked example, because it is the most instructive. Sensation to the breast and nipple arrives mainly through the lateral and anterior cutaneous branches of the intercostal nerves, with the fourth intercostal nerve carrying the dominant supply to the nipple-areola complex in most people. Those branches are small, they run in predictable but variable planes, and essentially every breast operation crosses at least some of them. That anatomy is why sensory change after breast surgery is the norm rather than the exception, and it is the same anatomy behind the sensory questions in nipple and areola reduction and behind the honest discussion of what a lift or an augmentation costs in feeling.

Three distinct mechanisms produce lasting pain from that starting point:

• Neuroma formation. A cut nerve tries to regenerate. If the growing fibers cannot find their distal path, they coil into a tangled bulb that fires spontaneously and on pressure. The clinical signature is a small, exquisitely tender point that reproduces the whole pain when pressed, sometimes with a shock radiating along the nerve's territory. That point is findable with a fingertip, which is why an examination matters more than an imaging study.
• Nerve entrapment and traction. A nerve caught in scar tissue, in a fascial repair, or against a device does not need to be cut to hurt. Implants placed under the pectoralis muscle sit directly against a moving muscle and its nerve supply, which is one of the mechanical arguments behind the shift described in the move toward pre-pectoral implant placement. Scaffolds and mesh add another fixed structure in the same field, as covered in what is actually being sewn inside a breast.
• Central sensitization. With sustained input from an injured nerve, the spinal cord and brain amplify. Thresholds drop, the painful area spreads beyond the nerve's actual territory, and light touch starts to register as pain. This is the mechanism that makes the condition self-sustaining, and it is the reason that fixing the peripheral problem late does not always fix the pain.

There is also the differential nobody should skip. Persistent breast pain after an implant is not automatically nerve pain. A tightening capsule generates real, mechanical, progressive discomfort, described in what the capsular contracture evidence actually shows. A delayed inflammatory reaction produces pain with swelling, as in the filler nodule that shows up a year later. Pain that arrives new after a period of comfort is a reason for an examination, not a reason for a stronger prescription.

The most modifiable risk factor is the first week

The short answer: of everything that predicts chronic pain at a year, the severity of uncontrolled acute pain in the first postoperative days is the one the surgical team can most directly change, which reframes early pain control as prevention rather than comfort.

The predictors that recur across studies fall into three groups.

Before surgery. Pre-existing pain anywhere in the body, particularly in or near the operative field. Ongoing opioid use. Younger age, consistently, in most breast series. Anxiety, depression, and pain catastrophizing, meaning the tendency to magnify and ruminate on pain, which is measurable with validated instruments and is among the more robust psychological predictors in the literature. Psychological screening in aesthetic consultations is usually framed around body image, as in screening for body dysmorphic disorder, but the same conversation could catch this.

During surgery. The extent of nerve handling, which is largely a function of the operation chosen rather than the skill applied. Longer operative time. Repeat surgery in a previously operated field, which is one more argument for taking the first operation seriously rather than treating revision as a routine second act, a theme running through what redo cases reveal about choosing a surgeon.

Immediately after. Severe acute pain in the first days, and the total duration of that severe pain. This finding is remarkably consistent, and it is the one with an obvious action attached.

That action is the multimodal and regional anesthesia approach already reshaping recovery for other reasons. Long-acting local anesthetic infiltration, and fascial plane blocks such as the pectoral nerve and serratus anterior blocks for chest work or transversus abdominis plane blocks for abdominal work, reduce early pain scores and opioid requirements substantially. The full regimen and its limits are covered in the retreat from opioids in plastic surgery recovery.

Here the evidence needs an honest boundary. Blocks and multimodal regimens are well supported for controlling acute pain. Whether they reliably prevent chronic pain months later is a separate and less settled question, with trials showing benefit in some settings and not others. And one intervention that was widely adopted specifically for this purpose has largely failed the test: a 2020 systematic review and meta-analysis in Anesthesiology examining perioperative gabapentinoids found no clinically meaningful reduction in acute pain and no convincing effect on chronic postsurgical pain, while confirming the sedation and dizziness side effects. Perioperative ketamine and intravenous lidocaine have modest and inconsistent supporting data.

So the accurate statement is narrower than the marketing version: controlling severe early pain is worth doing on its own merits, is associated with better long-term pain outcomes, and is the most plausible lever available. It is not a guarantee, and any practice promising that a block prevents chronic pain is overselling.

What can be done once it is established

The short answer: quite a lot, but the sequence matters, the responsible first step is excluding a mechanical cause, and the treatments that work on nerve pain are not the ones most patients have already tried.

The workup starts by ruling out the fixable structural problems: infection, a tightening capsule, implant malposition, a seroma, an unrecognized hernia, a suture or a scaffold under tension. Imaging and examination answer most of that. If a mechanical problem is found, treating it is the treatment.

If nothing mechanical explains it, the pathway looks like this:

• Neuropathic-specific medication. The internationally recommended first-line agents for neuropathic pain, summarized in the widely cited 2015 Lancet Neurology review from the neuropathic pain special interest group, are gabapentin and pregabalin, duloxetine, and the tricyclics such as amitriptyline and nortriptyline, with topical lidocaine as a useful local option. Note what is absent from that list: anti-inflammatories and opioids, which patients have usually been cycling through for months by the time anyone reframes the diagnosis.
• Diagnostic and therapeutic nerve blocks. A targeted block that abolishes the pain temporarily does two things: it confirms which nerve is generating the signal, and it identifies patients who may benefit from a procedure aimed at that nerve.
• Surgery on the nerve itself. For a confirmed, localized, palpable neuroma that fails medical management, excision alone has a long history of disappointing recurrence, because a cut nerve simply forms another neuroma. Modern techniques address that by giving the nerve end somewhere to go: targeted muscle reinnervation, which routes the nerve into a nearby motor nerve of an expendable muscle, and the regenerative peripheral nerve interface, which wraps the end in a small graft of muscle. Both came out of amputation care and have been applied more broadly, with encouraging results in the pain outcomes literature and a still-limited evidence base in aesthetic surgery specifically.
• Device or pocket revision. Where an implant is implicated, removal, a plane change, or capsule surgery is sometimes offered. It is a reasonable option and an uncertain one, and the honest framing is that it may help and may not, particularly once central sensitization is established. What removal does and does not do to the breast otherwise is covered in what happens to the skin after implant removal.
• Multidisciplinary pain management. For established, widespread, sensitized pain, the strongest evidence supports combined programs: medication, graded physical therapy, desensitization, and psychological approaches such as cognitive behavioral therapy or acceptance-based methods. Recommending psychological treatment for pain is routinely misread by patients as a suggestion that the pain is imaginary. It is not. It is a statement about which part of a nervous system is being treated.

The other thing that helps and costs nothing is being believed on time. A patient telling a practice at four months that something still burns should get an examination and a named diagnosis, not reassurance that swelling takes a year. Swelling does take a year, and the timeline in why the final result takes a year is real. Burning, electrical, clothing-triggered pain in a numb patch of skin is not swelling, and the two should not be filed together.

The honest summary

Most people who have cosmetic surgery recover, stop hurting, and never think about any of this. That is the ordinary outcome and it should be stated first, because an article about a persistent complication reads as a warning against the operation, and this one is not.

What is fair to say is that chronic postsurgical pain is a real, defined, coded diagnosis, that the operations most associated with it in the general surgical literature are anatomically the same operations performed for cosmetic reasons on the breast and the abdominal wall, and that the aesthetic field has published remarkably little about its own rate. Absence of data is being quietly treated as absence of risk. Those are different things.

There are three practical consequences. First, ask about the one-year number and listen to how the answer is constructed, because a surgeon who does not measure something cannot tell you it does not happen. Second, take the first week of pain control seriously, and treat a plan for regional blocks and multimodal analgesia as a quality signal rather than a comfort upgrade, since severe early pain is the most modifiable predictor available. Third, if pain is still present at three months with a burning or electrical character, particularly in skin that is also numb, name it, get a structural cause excluded, and understand that the drugs already in the cabinet are the wrong class for it.

The most avoidable version of this problem is not the pain itself. It is the year a patient spends being told that this is normal, taking medication that was never going to work, and concluding that complaining is pointless, while the treatments that actually address nerve pain sit one correct diagnosis away.